Yet, there is uncertainty, the next analysis reflected that PPP1R14A is negatively correlated with TMB/MSI in many tumors, which means that neoantigens, the target of immune cells, would be less in these cancer patients with high PPP1R14A, and immune checkpoint targeted therapy may be deflated as a result. This evidence concerns the gene PPP1R14A and cancer.